TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)

March 3, 2025 1:07 PM EST

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).

The analyst comments "TGTX stock is up >18% (XBI: -1%) on the back of positive comments on the 4Q call around 1Q trends for Briumvi (anti-CD20 drug in... More